Johnson & Johnson Innovation Names Winners of Inaugural Champions of Science – Africa Storytelling Challenge
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 15, 2019 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 14, 2019 Category: Pharmaceuticals Source Type: news

Janssen Announces Preliminary Results from Phase 2 GALAHAD Study in Adults with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Pathway Defects (DRD)
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 14, 2019 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Announces Agreement to Acquire Auris Health, Inc.
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 13, 2019 Category: Pharmaceuticals Source Type: news

FDA Advisory Committee Recommends Approval of SPRAVATOTM (esketamine) Nasal Spray CIII for Adults with Treatment-Resistant Depression
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 12, 2019 Category: Pharmaceuticals Source Type: news

U.S. FDA Approves DARZALEX ® (daratumumab) Split-Dosing Regimen
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 12, 2019 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in the 2019 CAGNY Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 5, 2019 Category: Pharmaceuticals Source Type: news

First Atrial Fibrillation Patient Treated in Biosense Webster U.S. IDE Study Evaluating High Power, Short Duration Ablation Catheter
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 5, 2019 Category: Pharmaceuticals Source Type: news

Janssen Enters Worldwide Collaboration and License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseases
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 31, 2019 Category: Pharmaceuticals Source Type: news

Janssen Announces ERLEADA ® (apalutamide) Phase 3 TITAN Study Unblinded as Dual Primary Endpoints Achieved in Clinical Program Evaluating Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 30, 2019 Category: Pharmaceuticals Source Type: news

New Study Suggests Surgical Stapler May Play Important Role in Reducing Common Complications Associated with Lung Surgery
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 28, 2019 Category: Pharmaceuticals Source Type: news

U.S. FDA Approves IMBRUVICA ® (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 28, 2019 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Reports 2018 Fourth-Quarter Results:
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 22, 2019 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Announces Research Study with Apple Watch to Help Improve AFib Outcomes Including Stroke Prevention
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 17, 2019 Category: Pharmaceuticals Source Type: news

Dr. Paul Janssen Award for Biomedical Research Issues 2019 Call for Nominations to Celebrate Champions of Science
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 10, 2019 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2019
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 2, 2019 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in 37th Annual JP Morgan Health Care Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 24, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to HostInvestor Conference Call on Fourth-Quarter Results
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 19, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Announces $5 Billion Share Repurchase Program
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 17, 2018 Category: Pharmaceuticals Source Type: news

Statement on Reuters Talc Article
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 14, 2018 Category: Pharmaceuticals Source Type: news

Janssen Submits Supplemental New Drug Application (sNDA) to FDA for XARELTO ® (rivaroxaban) to Prevent Venous Thromboembolism (VTE) in Acute Medically Ill Patients
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 14, 2018 Category: Pharmaceuticals Source Type: news

Janssen Signs Results-Based Contract with Oklahoma Health Care Authority (OHCA) for its Long-Acting Injectable Schizophrenia Medicines
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 13, 2018 Category: Pharmaceuticals Source Type: news

New Phase 3 data demonstrate superiority of TREMFYA ® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 12, 2018 Category: Pharmaceuticals Source Type: news

Cerenovus Launches Largest Global Registry to Study Stroke-Inducing Blood Clots Removed by Thrombectomy
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 11, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Works with U.S. PEPFAR Program to Expand Access for HIV Treatment-Experienced Children in the Developing World
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 7, 2018 Category: Pharmaceuticals Source Type: news

New Phase 3 Study Findings Show IMBRUVICA ® (ibrutinib) Plus Rituximab Significantly Improved Survival Compared to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Previously Untreated Patients Aged 70 or Younger with Chronic Lymphocytic Leukemia
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 4, 2018 Category: Pharmaceuticals Source Type: news

New DARZALEX ® (daratumumab) Phase 3 Study Shows Efficacy and Safety Data of Anti-CD38 Monoclonal Antibody in Patients with Newly Diagnosed Multiple Myeloma
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 4, 2018 Category: Pharmaceuticals Source Type: news

New Phase 3 CASSINI Data Presented on the Use of XARELTO ® (rivaroxaban) for Venous Thromboembolism (VTE) Prevention in High-Risk Cancer Patients
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 4, 2018 Category: Pharmaceuticals Source Type: news

Updated Data from Phase 1/2 Open-Label Study of BCMA-Directed CAR-T Cell Therapy LCAR-B38M Show Tolerable Safety Profile, High Overall Response and MRD Negative Rate in Treatment of Patients with Advanced Relapsed or Refractory Multiple Myeloma
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 4, 2018 Category: Pharmaceuticals Source Type: news

IMBRUVICA ® (ibrutinib) Plus Obinutuzumab Showed Significant Improvement in Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 3, 2018 Category: Pharmaceuticals Source Type: news

Janssen Affiliate Cilag GmbH International Enters Worldwide Collaboration and License Agreement with argenx for Cancer Immunotherapy Cusatuzumab
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 3, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Announces Participation in New Collaboration Funded by the UK to Support Vaccines for Pandemic Preparedness
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 3, 2018 Category: Pharmaceuticals Source Type: news

DARZALEX ® (daratumumab) Combination Regimens Show Positive Results for Newly Diagnosed and Relapsed Patients with Multiple Myeloma
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 1, 2018 Category: Pharmaceuticals Source Type: news

First Patient Treated In Biosense Webster U.S. Ide Study Evaluating Next Generation Balloon Ablation Catheter For Atrial Fibrillation
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 29, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in the BMO Prescriptions for Success Healthcare Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 26, 2018 Category: Pharmaceuticals Source Type: news

Janssen receives positive CHMP opinion for ERLEADA ™ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 16, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in the Citi ’s 2018 Global Healthcare Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 12, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in the Citi ’s 2018 Global Healthcare Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 12, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Launches Africa Innovation Challenge 2.0
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 9, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in the Credit Suisse 27th Annual Healthcare Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 6, 2018 Category: Pharmaceuticals Source Type: news

Janssen Shows Commitment to Advancing the Science and Treatment of Blood Cancers and Related Conditions With More Than 80 ASH 2018 Data Presentations From Differentiated Oncology and Cardiovascular Portfolios
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 1, 2018 Category: Pharmaceuticals Source Type: news

Janssen Reports Positive Topline Results for FLAIR Phase 3 Study of a Novel, Long Acting Injectable Two-Drug Regimen for the treatment of HIV-1
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 1, 2018 Category: Pharmaceuticals Source Type: news

U.S. FDA Approves INVOKANA ® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
(Source: Johnson and Johnson)
Source: Johnson and Johnson - October 30, 2018 Category: Pharmaceuticals Source Type: news

Janssen Presents Positive Long-Term Efficacy and Safety of SYMTUZA ® in Treatment-Naïve Adults with HIV-1
(Source: Johnson and Johnson)
Source: Johnson and Johnson - October 30, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Consumer Aligns to Big Goals In Environmental Sustainability, Signs New Plastics Economy Global Commitment
(Source: Johnson and Johnson)
Source: Johnson and Johnson - October 29, 2018 Category: Pharmaceuticals Source Type: news

New Data Presented at Psych Congress 2018 Sheds Light on the Significant Economic Burden of Treatment-Resistant Depression Amongst U.S. Veterans
(Source: Johnson and Johnson)
Source: Johnson and Johnson - October 29, 2018 Category: Pharmaceuticals Source Type: news

Court Issues Ruling in ZYTIGA ® Patent Infringement Litigation
(Source: Johnson and Johnson)
Source: Johnson and Johnson - October 26, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Unveils New Vaccines Launch Facility to Support Global Rollout of Novel Vaccines
(Source: Johnson and Johnson)
Source: Johnson and Johnson - October 25, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Human Performance Institute Expands Portfolio of C-suite Executive Development and Wellbeing Programs
(Source: Johnson and Johnson)
Source: Johnson and Johnson - October 24, 2018 Category: Pharmaceuticals Source Type: news